Drugs moving into the clinic: 5
The fifth in a series of periodic roundups of drugs that have moved
from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Argos Therapeutics | AGS-004 | HIV | dendritic cells loaded with disease mRNA designed to induce immune response |
| ThromboGenics & BioInvent International | TB-402 | anti-coagulent | human antibody designed to partially bind to Factor VIII and thus prevent coagulation but not increase the risk of bleeding side-effects |
| Adolor Corporation | ADL5859 | Pain management | Delta opioid receptor agonist |
| Pharmacopeia | PS433540 | hypertension and diabetic nephropathy | Dual-Acting angiotensin and endothelin Receptor Antagonist (DARA) - blocks action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors |
| Merck Serono & Rigel | R763 | Oncology - acute or chronic myeloid leukemia (AML or CML) or myelodysplastic syndrome (MDS) | multi-Aurora kinase inhibitor. NB. Phase I trial for solid tumours inititated Sept 2006 |
| Transgene | TG4040 (MVA-HCV) | Hepatitis C Virus Vaccine | expresses non structural proteins of the hepatitis C virus to induce an immune response |
